Brightseed, a San Francisco-based bioactives company, has launched Bio Gut Core™, a new nutraceutical ingredient clinically proven to strengthen the gut barrier and improve digestive wellness within weeks. Developed using Brightseed’s proprietary Forager® artificial intelligence platform, Bio Gut Core is a low-dose, ready-to-use ingredient designed for supplements and functional foods. Its debut comes alongside fresh human trial data demonstrating significant benefits for gut health, including enhanced gut barrier function and reduced bloating and abdominal discomfort, in as little as three weeks of use.

Digestive health is a major consumer priority and economic opportunity, with the global digestive health products market valued at over $51 billion. In the United States alone, an estimated 60–70 million people suffer from digestive diseases. Consumers are actively seeking solutions that target the gut barrier, an often-overlooked aspect of gastrointestinal health: according to Brightseed, 88% of surveyed consumers want products to help restore gut barrier function. The gut barrier serves as a critical “shield” in the digestive tract – it fosters a balanced microbiome, enables nutrient absorption, and blocks toxins from entering the bloodstream. A weakened barrier (sometimes called “leaky gut”) can lead to dysbiosis, inflammation, and symptoms like bloating and digestive pain. Until now, formulating supplements to support gut barrier integrity has been challenging, often requiring impractically large doses with limited efficacy. Brightseed’s Bio Gut Core aims to change that with a science-backed, concentrated solution.

AI-Powered Discovery of Key Gut Health Bioactives

 Brightseed’s proprietary Forager AI platform identified two bioactive compounds (NCT and NFT) from common plant sources to power the new Bio Gut Core™ ingredient. These natural compounds were discovered in dozens of ubiquitous plants, such as garlic and black pepper, using AI-driven analysis. The discovery exemplifies how advanced technology is uncovering nature’s solutions for human health.

Bio Gut Core’s effectiveness stems from a proprietary blend of two phytonutrients that Brightseed’s Forager® AI discovered in nature: N-trans-caffeoyltyramine (NCT) and N-trans-feruloyltyramine (NFT). These bioactive compounds were identified across many common plants (including garlic and black pepper) as having a unique impact on gut health. Research by Brightseed found that NCT and NFT act as agonists for HNF4α, a transcription factor known to play a key role in maintaining gut barrier integrity. In other words, the compounds activate a biological pathway that fortifies the gut lining. This mechanistic insight helps explain the observed benefits: by targeting HNF4α, NCT and NFT help support a stronger, less permeable intestinal barrier, which is crucial for overall digestive health.

Notably, Bio Gut Core delivers these benefits in a low-dose format, making it easy to incorporate into supplements and functional foods. “Bio Gut Core brings together two clinically-proven bioactives in one product to enable a more complete digestive health solution and effectively target the gut barrier,” Brightseed explained. This marks a breakthrough given that previous approaches to gut barrier support often required high doses or large volumes of fibre. By leveraging AI to pinpoint high-potency natural compounds, Brightseed has created an ingredient that achieves meaningful results with a small, convenient dose.

Clinically Validated Benefits in Just Three Weeks

The launch of Bio Gut Core is backed by results from a new double-blind, randomized, placebo-controlled trial on its bioactive components. In the study, participants who took the NCT+NFT blend experienced a significant improvement in gut barrier function after only three weeks, compared to placebo. They also reported notably less abdominal distension (bloating) and reduced digestive discomfort within the same period. Impressively, some individuals began noticing relief after just one week of supplementation, highlighting the ingredient’s rapid onset of action.

Beyond the quantitative clinical outcomes, Brightseed has highlighted the real-world impact on participants’ quality of life. Study participants provided glowing testimonials about their digestive improvements. One individual described the difference after a week of taking Bio Gut Core as “night and day,” noting they had “the best two weeks in a long time” once the supplement kicked in. Another participant called the experience “absolutely life changing” and said it “has given me some quality of life back”. These firsthand accounts reinforce the clinical data and put a human face on the results, suggesting that Bio Gut Core could offer tangible relief for people suffering from chronic gut issues.

Brightseed’s scientific team underscores that the trial results represent an important validation of their AI-guided discovery approach. “This study provides clinical proof that bioactives NCT and NFT significantly improve gut barrier function, delivering a much-needed solution to health companies and consumers alike,” said Swati Kalgaonkar, Brightseed’s Head of Medical & Scientific Affairs and Clinical Research. Equally noteworthy, Kalgaonkar added, are the dramatic improvements reported by participants – outcomes she said are “even more exciting than the clinical data” and “the reason Brightseed exists”.

The human study was commissioned by Brightseed and is currently under peer review, with anticipated publication in a scientific journal later this summer. The company is also sharing the findings with the scientific community: Brightseed is scheduled to present results from the trial at the upcoming American Society for Nutrition (ASN) NUTRITION 2025 conference on May 31, 2025. The conference session, entitled “From Side Stream to Mainstream: How AI-Discovered Bioactives Are Revolutionizing Gut & Metabolic Health Benefits in Consumer Goods,” will spotlight Bio Gut Core’s development as an example of AI-driven innovation in nutrition.

Addressing the $51 Billion Digestive Health Market

With gut health continuing to dominate wellness trends, Brightseed’s new ingredient comes at an opportune time for the industry. The digestive health products sector – from supplements to functional foods – is enormous and growing, estimated at over $50 billion globally.  A large segment of consumers struggles with persistent digestive issues like IBS, “leaky gut,” and related metabolic conditions, driving demand for more effective solutions. Lee Chae, PhD, Brightseed’s co-founder and CEO, noted that Bio Gut Core represents a “novel, nature-derived ingredient” entering the $51 billion digestive market, and described it as a “next-level solution” to provide relief for the “tens of millions of Americans” affected by debilitating digestive conditions.  By delivering clinically validated efficacy in a convenient form, Bio Gut Core gives supplement manufacturers and wellness brands a new tool to address these widespread consumer needs.

Chae also emphasized that the successful development of Bio Gut Core validates Brightseed’s broader platform and mission. The positive clinical results “further validate the ability of Brightseed’s AI-driven discovery to meaningfully improve human health and quality of life,” he said. Bioactives identified by artificial intelligence and backed by rigorous trials can rapidly translate into market-ready health products – a paradigm that could accelerate innovation across the nutraceutical industry. Brightseed has signalled that Bio Gut Core is just the beginning, with “big plans from here” as it expands its pipeline of AI-discovered, science-backed ingredients. The company’s portfolio already includes offerings like Bio Gut Fibre (an upcycled hemp fibre ingredient rich in the same bioactives NCT and NFT), and it plans to unveil additional bioactive-based solutions targeting other areas of health.

Innovating Nutraceuticals for Digestive Wellness

Brightseed’s launch of Bio Gut Core™ illustrates a growing trend at the intersection of technology and natural products in the nutraceutical sector. By harnessing AI to uncover efficacious plant compounds and validating them through clinical research, companies like Brightseed are pioneering a new model of evidence-based innovation in digestive wellness. For healthcare practitioners and product formulators, this AI-discovered ingredient offers a novel approach to strengthening gut health, one that is rooted in nature yet demonstrated with scientific rigour. As digestive wellness remains a top priority for consumers, Bio Gut Core signals how cutting-edge discovery methods can unlock next-generation nutraceuticals. This convergence of AI technology, clinically proven efficacy, and unmet market needs sets a promising precedent for the future of gut health solutions and functional ingredients in the wellness industry.

SFI Health™ EMEA, the regional division of global natural healthcare leader SFI Health™, has announced a strategic shift to localize the packing of its key product brands in South Africa. This move leverages domestic manufacturing capabilities and talent, reinforcing the company’s commitment to the South African market and economy.

Operating through its South African subsidiary since 2004, SFI Health™ offers a portfolio of clinically researched natural health supplements focused on microbiome, cognition, and overall well-being. The transition to local packing will enhance operational flexibility, enabling the company to tailor pack sizes more precisely to consumer demands while maintaining its high standards for product quality and efficacy.

Susan Lewis, Head of Sales Direct Markets EMEA and co-leader of the initiative, highlighted the broader significance of the project:
“This initiative goes beyond business optimization; it is a deliberate investment in our local communities. By sourcing packaging materials and labour domestically, we strengthen the regional supply chain, support local jobs, and contribute to South Africa’s economic resilience.”

This localization strategy aligns with SFI Health™’s sustainability objectives, reducing environmental impact by minimizing transportation needs and promoting a circular, locally anchored supply chain.

South Africa’s growing consumer market will benefit from improved availability and accessibility of SFI Health™’s key brands, which include:

• Equazen® – A globally respected product formulated with essential fatty acids to support cognitive health.
• KeenMind® – Clinically studied to enhance memory, concentration, and learning retention.
• Gincosan® – Combines standardized Ginkgo biloba and Panax ginseng extracts to combat mental fatigue and improve cognitive function.
• Ginsana® – Utilizes a proprietary natural ingredient to support immune function and physical endurance.

Headquartered in Australia, SFI Health™ operates across more than 50 countries, with its EMEA regional office in Lugano, Switzerland, overseeing commercial activities across Europe, the Middle East, and Africa. The company combines a pharmaceutical rigour with natural health solutions, advancing confidence in natural healthcare through evidence-based products and collaborative partnerships with healthcare professionals worldwide.SFI Health EMEA Localizes Key Brand Packaging in South Africa

Scarborough Health Network Receives $1 Million Gift from Sue Nathan and Roy Ratnavel to Support Mental Health Care

In a powerful testament to the strength of community and the transformative power of giving, Sue Nathan and Roy Ratnavel have donated $1 million to the Scarborough Health Network (SHN) Foundation, earmarked for expanding inpatient mental health services at Birchmount Hospital.

The significance of this gift runs deeper than dollars and cents. For Roy Ratnavel—a former political prisoner in Sri Lanka, survivor of civil war, and acclaimed author of Prisoner #1056—the cause is profoundly personal. After immigrating to Canada at 18 and building a distinguished career in finance, Ratnavel has remained deeply connected to Scarborough, the community that first welcomed him and his family.

“It’s crucial that we address the mental health needs of our community with compassion and understanding,” Ratnavel shared. “Sue and I are proud to support Scarborough Health Network in their vital work. My own experiences have shown me the importance of accessible and culturally sensitive mental health support, and we hope this gift will help to break down barriers and reduce stigma.”

Expanding Access to Mental Health Services

Scarborough Health Network is home to Ontario’s second-largest community-based mental health program, serving over 65,000 outpatients, 7,500 inpatients, and handling more than 10,000 referrals every year. These figures highlight the pressing need for expanded, equitable, and stigma-free mental health services in one of Canada’s most diverse regions.

The $1 million donation from Sue Nathan and Roy Ratnavel will directly support the expansion of inpatient mental health facilities at Birchmount Hospital, enabling SHN to reach more vulnerable individuals facing persistent mental health challenges and complex care needs. The gift also advances SHN’s ongoing efforts to provide culturally responsive care, an issue close to Ratnavel’s heart, particularly within the Tamil community and other newcomer populations.

“We are inspired by Roy’s story and incredible resilience, and grateful to Roy and Sue for their commitment to improving mental health care in Scarborough,” said Alicia Vandermeer, President & CEO of SHN Foundation. “This donation will make a substantial difference in the lives of individuals and families facing mental health challenges.”

Supporting the “Love, Scarborough” Campaign

This historic gift also supports the Love, Scarborough campaign, a bold fundraising initiative launched in 2022 by the SHN Foundation. The campaign aims to raise awareness and critical funds for Scarborough’s three hospitals, supporting emergency care, pioneering new healthcare models, and advancing research and education across the network.

With the slogan “SHN does more than anyone thought possible with less than anyone could imagine. Imagine what they could do with more,” the campaign calls attention to both the needs and the immense potential of Scarborough’s health system. Learn more at lovescarborough.ca.

About Scarborough Health Network

SHN is shaping the future of care for one of Canada’s most dynamic and multicultural communities. With three hospitals and several community-based sites, SHN provides essential and specialized health services and is an academic leader through partnerships with the University of Toronto and the Scarborough Academy of Medicine and Integrated Health.

Supported by visionary donors like Nathan and Ratnavel, SHN is building forward with innovation, inclusivity, and a relentless commitment to health equity.

The beverage landscape is undergoing a radical transformation as consumers increasingly prioritize function over flavour. What began as a niche market for health-conscious buyers has exploded into a global phenomenon, with analysts projecting the functional beverage sector could reach a staggering $618.8 billion by 2034. This seismic shift represents more than just changing consumer preferences—it signals a fundamental reimagining of what beverages can and should do for our health and well-being.

The New Era of Purpose-Driven Drinking

Today’s consumers no longer view beverages simply as thirst-quenchers or indulgent treats. Modern shoppers, particularly millennials and Gen Z, are demanding drinks that deliver measurable health benefits alongside refreshment. This paradigm shift is being driven by several powerful forces converging simultaneously: an aging population seeking preventative health solutions, time-pressed consumers wanting nutrition on the go, and a growing distrust of traditional pharmaceuticals pushing people toward natural alternatives.

Research and Markets forecasts the global functional beverage market will reach $175 billion by 2030, while Insightace Analytic presents an even more bullish projection of $618.8 billion by 2034. This explosive growth is being led by women consumers and Asia-Pacific markets, where clean-label products, plant-based ingredients, and scientifically validated benefits are becoming purchase prerequisites rather than nice-to-have features.

The Science of Functional Beverages

At the core of this revolution is a new generation of beverages engineered to deliver specific health outcomes. Unlike their vitamin-enhanced predecessors, today’s functional drinks utilize cutting-edge nutritional science to target precise physiological needs. The most sought-after benefits currently driving innovation include cognitive enhancement through nootropics, gut health optimization via advanced probiotic strains, stress reduction using adaptogenic herbs, and alcohol metabolism support—a particularly promising category that has seen remarkable scientific advancement in recent years.

Safety Shot (NASDAQ: SHOT) has emerged as a pioneer in this latter category with its clinically validated formula shown to reduce blood alcohol content. Published research in the Journal of Nutrition and Dietary Supplements demonstrates the drink’s ability to not only lower BAC but also improve next-day alertness—a combination that addresses both immediate and next-morning concerns for social drinkers.

From Lab to Shelf: The Functional Beverage Market Matures

The functional beverage sector is rapidly evolving from scattered niche products to a sophisticated, science-driven industry. Safety Shot’s trajectory exemplifies this maturation, having expanded from direct-to-consumer sales to nationwide retail distribution in under a year. The drink is now available through major retailers including 7-Eleven, Albertsons, and Vons, as well as e-commerce platforms like Amazon and Walmart.com.

This retail expansion has been accompanied by product innovation, including the recent introduction of a stick-pack format designed for convenience and trial. The company’s strategic acquisition of Yerbaé Brands further demonstrates the industry’s consolidation trend, combining complementary functional beverage lines to create a more robust product portfolio.

The Future of Functional: Where the Industry is Headed

Looking ahead, several key trends are poised to shape the next chapter of functional beverages. Personalization is emerging as a major frontier, with AI-driven formulations that can be tailored to individual health needs and genetic profiles. The alcohol alternative space continues to expand, catering to both sober-curious consumers and those seeking healthier ways to socialize. Perhaps most significantly, we’re seeing the lines blur between beverages, supplements, and even pharmaceuticals as functional drinks incorporate increasingly sophisticated active ingredients.

For investors and industry watchers, the functional beverage revolution represents one of the most dynamic opportunities in consumer goods today. As Safety Shot and other innovators continue to push boundaries, they’re not just creating new products—they’re redefining the very role beverages play in our daily health routines.

Stay ahead of the trends with IHRMAGAZINE.com—your source for cutting-edge insights on the future of food, beverage, and wellness innovation.

Every nation at the forefront of medical progress depends on comprehensive population health studies to unlock discoveries that shape better healthcare. For Canada, that essential resource is CanPath (the Canadian Partnership for Tomorrow’s Health), the country’s most extensive long-term health research initiative. With data from over 330,000 participants—nearly one in every hundred Canadians—CanPath examines how genetics, lifestyle, and environmental factors influence chronic diseases and cancer, offering insights that could transform prevention and treatment nationwide.

Foundations of a National Health Legacy

Born from the 2006 Canadian Strategy for Cancer Control, CanPath has grown into a collaborative network encompassing seven regional cohorts from coast to coast, including the BC Generations Project, Alberta’s Tomorrow Project, and the Atlantic Partnership for Tomorrow’s Health. For nearly two decades, this initiative has enabled critical research into cancer, chronic illness, and health disparities, thanks to the dedication of Canadians who have shared their health data for the greater good.

Yet despite its achievements, CanPath’s future is uncertain. Declining operational funding jeopardizes Canada’s ability to leverage this world-class dataset, putting the country at risk of falling behind in global health innovation.

The Critical Role of CanPath in Modern Health Research

Recent public health emergencies have underscored the importance of real-time, large-scale health data. CanPath’s contributions have been vital in tracking emerging health risks, identifying at-risk populations, and guiding policy responses. According to Dr. Fei-Fei Liu, Scientific Director at the Canadian Institutes of Health Research, “Deep, well-established cohorts like CanPath don’t just advance science—they save lives and reduce healthcare costs by enabling early intervention and prevention.”

Beyond cancer research, CanPath has expanded into environmental health and social determinants of well-being. A partnership with the Canadian Urban Environmental Health Research Consortium (CANUE) has enriched the platform with 17 new datasets on air quality, green spaces, and community health factors—aligning with Bill S-5’s recognition of every Canadian’s right to a healthy environment.

Strengthening Research Through Strategic Partnerships

Collaboration is key to CanPath’s success. A landmark agreement with the Canadian Institute for Health Information (CIHI) now integrates anonymized records on hospital visits, emergency care, and long-term stays with CanPath’s wealth of genetic and lifestyle data. This fusion creates unprecedented opportunities to study health trends and improve care delivery.

At the same time, CanPath is pioneering next-generation data security and accessibility with a cloud-based research platform that allows scientists to analyze sensitive health information without compromising privacy. This innovation opens doors for biotech advancements, precision medicine, and public-private research partnerships that could position Canada as a leader in health innovation.

A Call to Safeguard Canada’s Health Research Leadership

The Canadians who participate in CanPath do so with the belief that their data will drive meaningful change. Dr. Christine Williams of the Ontario Institute for Cancer Research emphasizes this trust, stating, “We owe it to these individuals—and to future generations—to ensure their contributions lead to lasting impact.”

But without stable, long-term funding, CanPath’s potential remains untapped. In an era where data shapes health policy and medical breakthroughs, Canada cannot afford to lose this vital resource. Investing in CanPath means investing in a stronger, more resilient healthcare system—one where diseases are detected earlier, treatments are more precise, and public health strategies are rooted in evidence.

The choice is clear: Canada either commits to sustaining its premier health research platform or risks surrendering its place at the forefront of global medical progress.

For more on health policy and innovation, visit IHR Magazine.

When Ottawa’s Fullscript first opened its doors in 2011, its founders had a simple yet ambitious vision: to bridge the gap between clinicians and patients by seamlessly integrating evidence-based supplement prescribing, advanced lab testing and adherence tools into everyday practice. Fast-forward to 2025, and that vision has drawn renewed backing from HGGC, Snapdragon Capital Partners and Leonard Green & Partners—an endorsement that bodes well for Canada’s burgeoning digital health sector.

A New Infusion of Confidence

The announcement landed in mid-May: HGGC and Snapdragon deepening their stakes in Fullscript, supported by a continuation vehicle led by Leonard Green & Partners. For investors who first came aboard in 2021, the deal isn’t just a moment to celebrate returns—it’s a signal that Fullscript’s patient-centred model remains ahead of the pack. “This investment allows us to continue advancing our technology, expanding our services, and empowering more practitioners to deliver personalized, proactive care,” says Fullscript co-founder and CEO Kyle Braatz.

From Start-Up to Scale-Up

Fullscript’s growth story is one of measured ambition. From its early days helping boutique naturopathic clinics place supplement orders, the platform now supports more than 100,000 providers and 10 million patients across North America. Its lab’s network—integrated directly into clinic workflows—has transformed what once was a fragmented process of bloodwork orders, sample tracking and follow-up into a single, clinician-friendly interface.

Yet what sets Fullscript apart is its focus on long-term outcomes. Through its patient adherence app, individuals can track their supplement routines, receive gentle reminders and access educational content curated by their practitioners. The result? Higher adherence rates, better health outcomes, and a reinforcing cycle of trust between patient and provider.

Powering Preventive Health in Canada

In Canada, where wait times and rising healthcare costs dominate headlines, Fullscript’s preventive ethos strikes a compelling chord. Dietitians, chiropractors and integrative physicians alike are embracing the platform to prescribe targeted nutritional interventions that can help stave off chronic conditions—often before they require more intensive medical treatments. Fullscript’s Ottawa-based team has grown in tandem, with plans to expand its local customer-support centre and deepen partnerships with Canadian labs and distributors to cut delivery times even further.

Aligning Investors and Innovators

For HGGC—managing over US$8 billion in commitments—the renewed investment fits squarely within a portfolio that prizes technology-driven health and wellness companies. Snapdragon Capital Partners, whose consumer-focused growth strategy has driven successes in franchising and B2B2C services, likewise sees Fullscript as emblematic of next-generation care delivery. Leonard Green & Partners’ continuation vehicle offered a dual benefit: it allowed earlier backers to realize some liquidity, while infusing fresh growth capital and ensuring all stakeholders remained aligned on Fullscript’s trajectory.

“This transaction reflects our conviction in Fullscript’s long-term value creation potential,” explains Mark Grabowski, Founder and Managing Partner at Snapdragon. David Fox and Garrett Hall, co-heads of LGP’s Sage strategy, add that they look forward to supporting Fullscript’s evolution as a market leader with “strong competitive positions and sustainable growth.”

What Lies Ahead

Armed with this new round of financing, Fullscript has its sights set on several strategic priorities: enhancing its machine-learning capabilities to deliver ever-more tailored supplement recommendations; rolling out richer analytics dashboards for clinicians; and exploring opportunities to extend its preventive-care toolkit into adjacent markets.

For Canadian practitioners and their patients, the upside is clear: faster access to reliable lab services, deeper insights into treatment effectiveness and more engaging tools to keep health goals front and centre. And for Fullscript—a once-young disruptor now entering its teenage years—this fresh infusion of confidence may be the catalyst that propels whole-person care into the mainstream.

Photo: Exterior of Pharmavite’s new 225,000 sq ft manufacturing and R&D centre in New Albany, Ohio.

New Albany, Ohio – Pharmavite LLC, the U.S.-based maker of Nature Made® vitamins, has officially opened its newest manufacturing and research & development facility in New Albany, signalling a significant expansion of its vitamin gummy production and innovation capabilities. The 225,000 sq ft site represents a US $250 million investment—Pharmavite’s first in Central Ohio—and is forecast to create 225 new jobs, with room for further growth on the adjacent property.

A Strategic Choice for Growth
“Our decision to locate in New Albany followed an exhaustive site-selection process,” says Pharmavite CEO Jeff Boutelle. “We’re proud to join this emerging hub of science, innovation and technology and to be embraced by a community that prioritizes wellness.” Since breaking ground in 2023, Pharmavite has collaborated with JobsOhio, One Columbus and the City of New Albany to ensure the facility aligns with regional economic and health-focused objectives.

Boosting Vitamin Gummies Production
Vitamin gummies have surged in popularity, nearly doubling in market size since 2019, with Nature Made leading in dollar-growth for the category in 2024. The New Albany plant will house two dedicated gummy production lines, warehouses and state-of-the-art laboratories, enhancing output and quality control for both Nature Made and Pharmavite’s other brands, including MegaFood®.

Gummies Innovation Centre of Excellence
A hallmark of the new site is the Gummies Innovation Centre of Excellence, where product development and scientific research will be co-located. This integrated approach seeks to accelerate formulation cycles and optimize nutrient stability in chewable formats, a critical factor as consumers increasingly seek convenient, science-backed supplements. “Bringing R&D under one roof allows for more agile innovation and faster consumer access to cutting-edge products,” explains Ray Gosselin, Pharmavite EVP and COO.

Beyond manufacturing, Pharmavite has committed to being an active community partner, supporting local initiatives such as Pelotonia, Healthy New Albany and the Mid-Ohio Food Collective. “This investment is more than bricks and mortar; it’s a long-term pledge to Central Ohio’s prosperity and well-being,” adds Boutelle. New Albany Mayor Sloan Spalding notes that Pharmavite’s arrival bolsters the city’s Health and Life Sciences cluster, reinforcing its reputation as a leading business park.

Zevia PBC (NYSE: ZVIA), the maker of naturally sweetened, zero-sugar beverages, delivered first-quarter results that landed at the upper end of guidance and showcased margin improvements despite a modest revenue dip. Net sales came in at US $38.0 million, down 2 percent from US $38.8 million in Q1 2024, reflecting heightened promotional activity even as pricing actions and a small volume uptick partially offset channel disruptions Nasdaq.

Strong Margin Performance
Gross profit margin climbed to a record 50.1 percent, a 4.4-point year-over-year gain driven by lower product costs and more efficient inventory management, partially tempered by increased trade spend Nasdaq. This marks the highest quarterly margin in Zevia’s public-company history and underscores the early benefits of its Productivity Initiative, which also fuelled a 25.8 percent reduction in selling expenses as a percentage of sales Nasdaq.

Improved Profitability Metrics
Zevia narrowed its net loss to US $6.4 million (US $0.08 per share), down from US $7.2 million (US $0.10 per share) in the year-ago quarter. Non-GAAP adjusted EBITDA loss improved by US 2.2 million to US 3.3 million, outperforming the company’s own forecast of a US 5.6 million to US 6.0 million loss, largely thanks to stronger-than-anticipated margin expansion Nasdaq.

Operational Investments and Cost Savings
Selling and marketing outlays rose to US $15.3 million (40.3 percent of net sales), primarily reflecting a US 3.5 million increase in marketing spend aimed at bolstering brand awareness through new campaign activations and innovation support. Conversely, direct selling costs fell significantly, fueled by freight and warehousing efficiencies achieved under the Productivity Initiative. General and administrative expenses declined to US $7.0 million, or 18.4 percent of sales, down from 20.9 percent in Q1 2024 Nasdaq.

Market Reaction and Analyst Commentary
Zevia’s earnings beat consensus forecasts, with adjusted EPS of –US $0.08 surpassing the –US $0.10 estimate by roughly 20 percent; some analysts noted this represented a 31 percent upside to street expectations Yahoo Finance. Despite the modest sales contraction—below analyst revenue forecasts of approximately US $40.8 million—the stock saw a positive reaction, buoyed by confidence in Zevia’s path to profitability and sufficient liquidity, as the company held US $27.7 million in cash with no debt and an unused US $20 million credit line at quarter-end Nasdaq.

Maintained 2025 Outlook
Management reaffirmed full-year guidance, expecting net sales between US $158 million and US $163 million and an adjusted EBITDA loss of US $8 million to US $11 million. The second-quarter outlook calls for US $40.5 million to US $42.5 million in net sales and an adjusted EBITDA loss of US $2.2 million to US $2.9 million Nasdaq. Zevia emphasizes reinvestment of productivity gains into marketing and innovation, alongside distribution expansion to deepen penetration in both core and emerging retail channels.

With record margins underscoring the efficacy of its cost-management programmes and a sharpened focus on brand building and product pipeline expansion, Zevia is positioning itself to capitalize on growing consumer demand for clean-label, zero-sugar beverages. As it navigates the balance between promotional intensity and profitability, industry observers will be watching for sustained volume growth and further margin optimization through the remainder of 2025.